Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228686 | PMC |
| http://dx.doi.org/10.21037/tau-23-673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Curr Urol Rep
October 2024
Department of Urology, Northwell Health, Manhasset, NY, USA.
Purpose Of Review: The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.
Recent Findings: The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs.
Absence of Race/Ethnicity Reporting in Clinical Trials of True Minimally Invasive Surgical Therapies for the Treatment of Benign Prostatic Hyperplasia.
Urology
October 2024
Division of Urology, Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montreal, QC, Canada. Electronic address:
Objective: To assess the extent of racial reporting and enrollment in randomized controlled trials (RCTs) of minimally invasive surgical therapies (MIST) for the office-based treatment of benign prostatic hyperplasia (BPH).
Methods: A systematic review was conducted for RCTs assessing 6 office-based MISTs: transurethral microwave thermotherapy (TUMT), prostatic artery embolization, prostatic urethral lift, temporary implantable nitinol device, water vapor thermal therapy, and Optilume. MEDLINE, Embase, and the Cochrane CENTRAL databases were searched up to November 3, 2023.
Advances in Outpatient Therapies and Treatment of Benign Prostatic Hyperplasia: A Comprehensive Review for Men's Health.
Med Clin North Am
September 2024
Division of Urology, Department of Surgery, Emory University, 1365 Clifton Road NorthEast, Building B 1st Floor, Suite 1400, Atlanta, GA 30322, USA.
Article Synopsis
- Benign prostate hyperplasia (BPH) is common among men and can be managed through various methods: behavioral changes, medications, and surgery.
- Recently, β3-agonists have been introduced for treating overactive urinary tract symptoms, enhancing medical therapy options.
- There has been a surge in minimally invasive and surgical treatment options over the last decade, allowing healthcare providers to customize BPH treatments based on individual patient needs and disease specifics.
The Optilume BPH Catheter System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Transl Androl Urol
June 2024
Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Long-term outcomes after treatment with Optilume BPH Four-year results from the EVEREST study.
Can Urol Assoc J
November 2024
Clínica Unión Medica, Santiago de los Caballeros, Dominican Republic.
Introduction: The purpose of this study was to gather initial safety and efficacy data with the Optilume BPH Catheter System for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Methods: A total of 80 men with moderate-to-severe LUTS secondary to BPH were enrolled and treated with the Optilume BPH Catheter System. Symptoms were evaluated using the International Prostate Symptom Score (IPSS) and Benign Prostatic Hyperplasia-Impact Index (BPH-II).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!